Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH)

Background Autoimmune hepatitis (AIH) is a substantial UK health burden, but there is variation in care, facilities and in opinion regarding management. We conducted an audit of service provision and care of patients with AIH in 28 UK hospitals. Methods Centres provided information about staffing, infrastructure and patient management (measured against predefined guideline-based standards) via a web-based data collection tool. Results Hospitals (14 university hospitals (UHs), 14 district general hospitals (DGHs)) had median (range) of 8 (3–23) gastroenterologists; including 3 (0–10) hepatologists. Eight hospitals (29%, all DGHs) had no hepatologist. In individual hospital departments, there were 50% (18–100) of all consultants managing AIH: in DGH’s 92% (20–100) vs 46% (17–100) in UHs. Specialist nurses managed AIH in only 18%. Seventeen (61%) hospitals had a histopathologist with a liver interest, these were more likely to find rosettes than those without (172/795 vs 50/368; p<0.001). Of 999 steroid-treated patients with ≥12 months follow-up, 25% received steroids for <12 months. After 1 year of treatment, 82% of patients achieved normal serum alanine aminotransaminase (ALT); this was higher in UHs than DGHs. Three-monthly liver blood tests were inadequately recorded in 26%. Of potentially eligible patients with liver decompensation, transplantation was apparently not considered in 5% (n=7). The same standards were attained in different types of hospital. Conclusion Management of AIH in UK hospitals is often shared between most gastroenterologists. Blood test monitoring and treatment duration are not always in line with recommendations. Some eligible patients with decompensation are not discussed with transplant teams. Care might be improved by expanding specialist input and management by fewer designated consultants.

[1]  M. Mckee,et al.  Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK , 2019, The Lancet.

[2]  M. Manns,et al.  Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  D. Stocken,et al.  The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility , 2018, Hepatology.

[4]  A. Lohse,et al.  Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom , 2018, Alimentary pharmacology & therapeutics.

[5]  J. McGonigle,et al.  Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[6]  M. Karajeh,et al.  Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis , 2015, The American Journal of Gastroenterology.

[7]  H. Vilstrup,et al.  Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. , 2014, Journal of hepatology.

[8]  H. Dhaliwal,et al.  PTU-032 Management of autoimmune hepatitis: a UK-wide survey , 2012, Gut.

[9]  A. Austin,et al.  Service provision for liver disease in the UK: a national questionnaire-based survey. , 2012, Clinical medicine.

[10]  M. Heneghan,et al.  British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis , 2011, Gut.

[11]  M. Campbell,et al.  Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. , 2011, Gastroenterology.

[12]  C. Stedman,et al.  Population‐based epidemiology study of autoimmune hepatitis: A disease of older women? , 2010, Journal of gastroenterology and hepatology.

[13]  M. Manns,et al.  Diagnosis and management of autoimmune hepatitis , 2010, Hepatology.

[14]  A. Bergquist,et al.  Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study , 2008, Scandinavian journal of gastroenterology.

[15]  D. R. Parker,et al.  Type I autoimmune hepatitis is primarily a disease of later life. , 1997, QJM : monthly journal of the Association of Physicians.

[16]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[17]  J. Drenth EASL Clinical Practice Guidelines: Autoimmune hepatitis. , 2015, Journal of hepatology.

[18]  J. Primo,et al.  [Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain)]. , 2004, Gastroenterologia y hepatologia.